Melanoma
Multiomic Profiling Uncovers Predictors of Melanoma Response to Immunotherapy
A model based on the results could predict treatment response but was less able to forecast resistance, suggesting heterogeneous mechanisms.
After a promising pilot study, researchers at the University of Helsinki are starting a larger investigation of patients' response to drugs selected via this method.
Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma
FoundationOneCDx will also automatically be a companion diagnostic for future BRAF inhibitors approved by the FDA that target specific BRAF mutations.
Deepcell, University of Zurich Partner to Study Melanoma Microenvironment
Investigators will use Deepcell’s AI-powered platform to isolate cancer cells, profile the tumor microenvironment, and study cell phenotype and function.
UK Researchers Show Cytotoxic T-Cell Level Predicts Melanoma Immunotherapy Response
A Science Immunology paper details how patients with more cytotoxic effector T cells in peripheral blood at baseline respond better to checkpoint inhibitors.